AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Updates in Checkpoint Inhibitor Induced Toxicities

Description

The presentation discusses checkpoint inhibitor-induced toxicities, focusing on how to manage these patients effectively. The impact of immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment, leading to improved outcomes for conditions such as metastatic melanoma. However, these therapies can lead to immune-related adverse events (irAEs), with dermatological issues being the most common. The presenter emphasizes the importance of understanding the diverse nature of these toxicities, which can range from mild skin irritations to significant complications like colitis or adrenal insufficiency. A thorough drug history for patients receiving immunotherapy is crucial, as previous treatments can still affect their current condition. The presentation discusses specific skin reactions, such as lichenoid eruptions, psoriasis, and mucocutaneous diseases, and how to differentiate between them. Often, dermatologists are called upon to manage these rashes, and understanding the grading of these eruptions is essential for effective treatment. The presenter also highlights the importance of avoiding premature treatment interruptions and the need for collaboration between dermatologists and oncologists to optimize patient outcomes. Several case studies illustrate nuanced approaches to managing adverse reactions, underscoring that not all symptoms during therapy are necessarily related to the immunotherapy itself. A comprehensive understanding of the interaction between immunotherapy and dermatological conditions can significantly enhance patient management and quality of life.

View more

Conclusions

  • Checkpoint inhibitors have revolutionized cancer treatment, significantly improving survival rates in patients with previously high mortality malignancies like metastatic melanoma.
  • The use of immune checkpoint inhibitors can lead to a wide range of adverse events, particularly affecting the skin, bowel, and endocrine system.
  • These adverse events cannot easily be predicted, and patients may experience multiple coexisting immune-related side effects.
  • Management of immune-related adverse events requires a careful and tailored approach, often involving collaboration between dermatologists and oncologists.
  • Effective treatment strategies for immune-related skin reactions include topical therapies, phototherapy, and, in some cases, systemic medications like dupilumab.
  • Steroid use in treating immune-related adverse events may be counterproductive due to their potential to impair the effectiveness of checkpoint inhibitors.
  • Biologic therapies, particularly targeted at immune-related dermatitis, are increasingly used, and they may offer a better outcome for patients without compromising cancer treatment.
  • Monitoring the trajectory of skin eruptions following immunotherapy is crucial for guiding treatment decisions.
  • Proper diagnosis is essential, as not all dermatological conditions in immunotherapy patients are due to the treatments; differential diagnosis should be considered.
  • The response to treatment varies widely among patients, necessitating personalized care approaches.
  • Chang E, Pelosof L, Lemery S, et al. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist. 2021;26(10):e1786-e1799. doi:10.1002/onco.13887
  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LI, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14. PMID: 29442540; PMCID: PMC6481621.
  • Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226. PMID: 27411054; PMCID: PMC6108080.
  • Bur, Delfina et al. "A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes." Journal of the American Academy of Dermatology vol. 87,6 (2022): 1394-1395. doi:10.1016/j.jaad.2022.08.001.
  • Nelson, Caroline A et al. "Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes." Journal of the American Academy of Dermatology vol. 87,6 (2022): 1400-1402. doi:10.1016/j.jaad.2019.12.068.
  • Said, Jordan Taylor et al. "Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review." Journal of the American Academy of Dermatology vol. 87,2 (2022): 399-400. doi:10.1016/j.jaad.2022.02.030
  • Halle, Briana Rose et al. "Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy." Journal for immunotherapy of cancer vol. 9,10 (2021): e003066. doi:10.1136/jitc-2021-003066.
  • Petrelli, Fausto et al. "Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis." Cancers vol. 12,3 546. 27 Feb. 2020, doi:10.3390/cancers12030546
  • Orgulescu, J Bryan et al. "Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,1 (2021): 276-287. doi:10.1158/1078-0432.CCR-20-2291.
  • Fuca G, Galli G, Poggi M, et al. . Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO open 2019.
  • Said, Jordan T et al. "Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid." Journal of the American Academy of Dermatology vol. 88,3 (2023): 670-671. doi:10.1016/j.jaad.2022.06.1186.
  • Lo, Jonathan J et al. "Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 30,2 (2022): 989-994. doi:10.1007/s00520-021-06548-4.